Potential of <sup>1</sup>H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy

Journal of Magnetic Resonance Imaging - Tập 30 Số 4 - Trang 842-848 - 2009
Virendra Kumar1, N. R. Jagannathan1, Rajeev Kumar2, Rishi Nayyar2, Sanjay Thulkar3, Siddhartha Dutta Gupta4, Ashok K. Hemal2, Narmada P. Gupta2
1Department of NMR & MRI Facility, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
2Department of Urology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
3Department of Radio-diagnosis, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
4Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

Tóm tắt

AbstractPurposeTo evaluate the potential of MR spectroscopic imaging (MRSI) to segregate patients who, upon prostate biopsy, are more likely to show a malignancy in the peripheral zone (PZ) of the prostate gland.Materials and MethodsBefore biopsy, MRSI was carried in 123 men with elevated prostate specific antigen level or an abnormal digital rectal examination. After the MRSI investigation, all patients underwent systematic transrectal ultrasound guided biopsy and were categorized using standard random number tables into the following two groups: (i) Group I, a 62 member training set; and (ii) Group II, a 61‐member test set. The cutoff value for the [citrate/(choline+creatine)] ratio for patients in the training set was obtained using the receiver operating characteristic (ROC) curve method. This value was then applied to the test set of patients as well.ResultsThe ROC method gave a cutoff value of 1.2 for the [Citrate/(Choline+Creatine)] ratio. When applied as a malignancy‐predictor to the test group of patients (Group II), the ROC method generated the following results: sensitivity, 77%; specificity, 83%; negative predictive value, 93%; positive predictive value, 55% and accuracy, 82%.ConclusionThe results indicate that patients who are deemed as malignancy‐positive in the PZ by MRSI using the ROC cutoff may be subjected to prostate biopsy to confirm the diagnosis of cancer. J. Magn. Reson. Imaging 2009. © 2009 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

National Cancer Registry Program, 2001, Consolidated report of the population based cancer registries

Terris MK, 2002, Campbell's urology, 3038

10.1016/j.rcl.2006.07.008

10.1148/rg.271065078

10.1016/j.rcl.2006.10.008

10.1148/radiol.2431030580

10.1016/j.mric.2008.07.005

10.1016/j.mric.2008.07.002

10.1097/MOU.0b013e3282f19d01

10.1097/01.ju.0000094958.23276.c4

10.1002/jmri.10172

10.1016/S0090-4295(99)80016-8

10.1148/radiology.198.3.8628874

10.1002/mrm.1910370212

10.1016/S0730-725X(99)00006-5

10.1007/s00240-003-0372-8

10.1148/radiology.206.3.9494502

10.1148/radiology.213.2.r99nv23473

10.1148/radiology.213.2.r99nv26481

10.1148/radiol.2313031391

10.1016/S0360-3016(01)02609-8

10.1016/j.eururo.2005.01.015

10.1006/jmra.1996.0242

10.1148/radiol.2231010575

10.1016/S0360-3016(98)00502-1

10.1016/S0360-3016(00)00557-5

10.1148/radiol.2363040615

10.1002/nbm.1083

10.1002/mrm.20103

10.1016/S0090-4295(96)00250-6

Heerschap A, 1997, In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue, Anticancer Res, 17, 1455

10.1002/(SICI)1522-2594(200001)43:1<17::AID-MRM3>3.0.CO;2-6

10.1002/mrm.1159

10.1016/j.mri.2006.01.001

10.1148/radiol.2452062201

10.1148/radiol.2462070368

10.1148/radiol.2333030672

10.1097/01.ju.0000118380.90871.ef

10.1148/radiol.2381041675

10.2214/AJR.06.0165

10.1002/jmri.20793

Thông tin
Thông tin xuất bản

Journal of Magnetic Resonance Imaging

Tập 30 Số 4

842-848

Thông tin tác giả